{"ok":true,"trend":{"id":351090,"platform":"news","region":"global","key":"keros therapeutics enrolls first patient in phase 2 rinvatercept dmd trial","title":"Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial","url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMHRlWnpiRzlYM0RxenhPMHZsc0N6NFRsQUNDcXQ0cmNBYksxcmt0SEhVS21PNWdJOWpwbmFRUjFUUjFfYmRhNExndXR2UFRMV0pzekZRaDN5NkxWNUtUUUFjaW16TDJCb3FZUVp4RUZsVXlUbGxpU0tWeEdwQ2FnaFFrUVlZcjRRbTNYOGtISXcxa3l4Z0pCd2dUWXY4eU1uLWRXXzV3UmF6emdGM0FuVlFBY0ZKSEY2UUE?oc=5","first_seen":"2026-09-29T11:12:53.304309Z","last_seen":"2026-09-29T16:40:54.450521Z","last_rank":37,"peak_rank":37,"last_volume":null,"peak_volume":0,"seen_count":5,"score":0.7353125,"category_hint":"medicine","section":"health","category":"medicine","summary":"Keros Therapeutics has dosed the first patient in a Phase 2 clinical trial of rinvatercept, an investigational therapy for Duchenne muscular dystrophy. The milestone marks the start of patient enrollment in the study, a key step in testing whether the drug can benefit people with the progressive muscle-wasting disease. Details on trial sites and timelines have not been widely reported yet.","why":"The start of patient dosing is a notable pipeline milestone for a potential new DMD treatment.","tone":"neutral","entities":["Keros Therapeutics","rinvatercept","Duchenne muscular dystrophy"],"summarized_at":"2026-09-29T17:16:57.531959Z","meta":{"via":"scan","lang":"en","term":"clinical trial","source":"The Clinical Trial Vanguard","published":"Tue, 29 Sep 2026 12:33:45 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-29T11:12:53.304309Z","rank":37,"volume":null},{"captured_at":"2026-09-29T12:34:54.901290Z","rank":37,"volume":null},{"captured_at":"2026-09-29T13:56:53.907524Z","rank":37,"volume":null},{"captured_at":"2026-09-29T15:18:53.739621Z","rank":37,"volume":null},{"captured_at":"2026-09-29T16:40:54.450521Z","rank":37,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMHRlWnpiRzlYM0RxenhPMHZsc0N6NFRsQUNDcXQ0cmNBYksxcmt0SEhVS21PNWdJOWpwbmFRUjFUUjFfYmRhNExndXR2UFRMV0pzekZRaDN5NkxWNUtUUUFjaW16TDJCb3FZUVp4RUZsVXlUbGxpU0tWeEdwQ2FnaFFrUVlZcjRRbTNYOGtISXcxa3l4Z0pCd2dUWXY4eU1uLWRXXzV3UmF6emdGM0FuVlFBY0ZKSEY2UUE?oc=5","author":"clinicaltrialvanguard.com","title":"Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial","snippet":null,"posted_at":"2026-09-29T07:43:59Z","likes":null}],"elsewhere":[],"window":"7d"}}